Previous research indicates that SMAD3 is overexpressed in advanced prostate cancer tissues and promotes CRPC cell proliferation.[41] NFIB facilitates tumor cell proliferation and resistance in hormone‐dependent breast cancer and colorectal cancer.[42] NFIB is also identified to promote EMT and metastasis of CRPC.[43] Initially identified as an oncogene in B‐cell lymphoma, BCL6 drives malignant phenotypes by inhibiting proliferation and DNA damage checkpoints, while obstructing terminal B‐cell differentiation. Here, BCL6 is linked to Familial prostate cancer.